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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYThe development of cell replacement strategies to repair the injured brain has gained considerable attention, with a particular interest in
mobilizing endogenous neural stem and progenitor cells (known as neural precursor cells [NPCs]) to promote brain repair. Recent work
demonstratedmetformin, a drug used tomanage type II diabetes, promotes neurogenesis.We sought to determine its role in neural repair
following brain injury. We find that metformin administration activates endogenous NPCs, expanding the size of the NPC pool and pro-
moting NPCmigration and differentiation in the injured neonatal brain in a hypoxia-ischemia (H/I) injury model. Importantly, metfor-
min treatment followingH/I restores sensory-motor function. Lineage tracking reveals thatmetformin treatment followingH/I causes an
increase in the absolute number of subependyma-derived NPCs relative to untreated H/I controls in areas associated with sensory-motor
function. Hence, activation of endogenous NPCs is a promising target for therapeutic intervention in childhood brain injury models.INTRODUCTION
Perinatal hypoxic-ischemic (H/I) insult is an important
cause of brain injury and can result in long-term neurolog-
ical complications, ranging frommild behavioral deficits to
severe seizure, intellectual disability, and/or cerebral palsy.
Neural injury results from excitotoxicity, inflammation,
and oxidative stress, leading to a loss of oligodendrocytes
and neurons, which are particularly sensitive to H/I
(Deng, 2010). With the exception of rehabilitation, there
are no established treatments available to improve behav-
ioral deficits in these patients to date.
The development of cell replacement strategies to repair
the injured brain has gained considerable attention, with a
particular interest inmobilizing endogenous neural precur-
sor cells (NPCs). Several studies have investigated the
impact of H/I on the germinal zone, a region that contains
multipotent NPCs. It has been shown that neural stem
cells (NSCs) remain resilient to this insult (Romanko
et al., 2004) and can regenerate neurons and oligodendro-
cytes following H/I, albeit to a very limited extent (Felling
et al., 2006; Ong et al., 2005; Plane et al., 2004; Yang and
Levison, 2006; Yang et al., 2007; Zaidi et al., 2004).This
injury-induced activation leads to a rare fraction of cells
migrating to the injury site, which is not sufficient for
self-repair (Ikeda et al., 2005). With the goal of developing166 Stem Cell Reports j Vol. 5 j 166–173 j August 11, 2015 j ª2015 The Autnew methodologies to enhance NPC activation in the
neonatal brain and promote neural repair following H/I,
we have built on successful NPC activation strategies that
lead to tissue formation and functional recovery using
small molecules tomobilize endogenous NPCs (Erlandsson
et al., 2011; Kolb et al., 2007). Previous work has demon-
strated that atypical PKC-dependent phosphorylation of
CREB-binding protein (CBP) on serine 436 is necessary
for enhancing differentiation in cortical precursor cells
(Wang et al., 2010). Moreover, this pathway is activated
bymetformin, an AMPK agonist, shown to promote neuro-
genesis and enhance spatial memory in uninjured mice
(Wang et al., 2012). Based on these findings, we asked
whether metformin could be used to stimulate subepen-
dyma (SE)-derived NPCs and promote repair of the H/I-
injured neonatal murine brain.RESULTS
Metformin Expands the Stem Cell Pool and Promotes
Differentiation via the aPKC-CBP Pathway in
Neonatal Pups, In Vitro
It is currently unknown whether metformin acts on the
NSCs, their downstream progeny, or both that ultimately
leads to enhanced neurogenesis. To test if metformin hadhors
Figure 1. Metformin Increases the Stem Cell Pool and Promotes Differentiation via the aPKC-CBP Pathway in Neonatal Pups
(A) Metformin was added at various concentrations to SE-derived NPCs. Neurosphere numbers were assayed following 7 days in culture
(n = 4 independent experiments, one-way ANOVA). In CBP S436A mutant mice, SE-derived NPCs were grown in either 0 ng/ml or 100 ng/ml
metformin (n = 13 mice, t test).
(B) Fold increase of O4-positive oligodendrocytes is shown (n = 9/group, t test).
(C) Fold increase of bIII-tubulin-positive neurons within a neurosphere is shown (n = 5/group, t test).
(D) Immunostaining for O4 (purple), bIII-tubulin (green), and Hoechst (blue) in cultures in the absence or presence of metformin during
the proliferation and differentiation phases is shown. Scale bars, 20 mm. Data are presented as mean ± SEM. *p < 0.05, ***p < 0.001,
****p < 0.0001.direct effects on NSCs, we used an in vitro, colony-forming
assay, termed the neurosphere assay on postnatal day 8 (P8)
pups from C57/BL6 (control) and CBP S436A mice (CBP
S436A mutants harboring a point mutation from serine
to alanine in the CBP gene specifically at the aPKC phos-
phorylation site) (He et al., 2009). Phosphorylation at
serine 436 has been shown to be essential for neural differ-
entiation in embryonic precursors; hence, we predicted
that direct effects of metformin on NPCs would not be
seen in CBP S436Amutantmice. Briefly, the SE is dissected,
dissociated, and plated into single cells. Over a period of
7 days, single NSCs proliferate to form a free-floating col-
ony of cells known as a neurosphere. Each individual neu-
rosphere is amixed population of stem and progenitor cells
(Morshead et al., 2002). In primary culture, an increase in
the total numbers of neurospheres indicates an expansion
of the stem cell pool. In the presence of metformin, we
observed a significant (>2-fold) increase in the numbers
of primary neurospheres in control mice, whereas this
effect was lost in CBP S436A mutant mice (Figure 1A).
Further, primary P8 SE-derived neurospheres grown and
differentiated in culture in the presence of metformin
gave rise to significantly more oligodendrocytes (1.9-fold
increase) and neurons (3.3-fold increase) compared to con-
trols (Figures 1B–1D), and this effect was lost for CBP S436A
mutants cultured in the same conditions (data not shown).
Thus, metformin expands the stem cell pool and promotesStem Coligodendrogenesis and neurogenesis from the early post-
natal brain via the aPKC-CBP pathway.
Functional Recovery in Injured Mice following
Metformin Treatment
We asked if administration of metformin was able to
enhance brain repair in a well-established model of
neonatal brain injury (Vannucci and Vannucci, 2005; Van-
nucci et al., 1999). P8 pups received a left common carotid
artery ligation followed by hypoxia for 1 hr. H/I-injured
pups revealed sensory-motor deficits, with increased
latencies in the righting reflex motor task and decreased la-
tencies in the hind limb suspension task at 1 hr and 4 days
post-H/I, respectively, when compared to uninjured pups
(Figures 2A–2C; Figure S1). Metformin was delivered to
neonatal pups starting 24 hr post-H/I via their lactating
mothers, which had 7-day micro-osmotic pumps im-
planted subcutaneously (20 mg/kg/day), or by subcutane-
ous injection directly into the pups (20 mg/kg/day). We
first assayed for the effects of H/I and/or metformin treat-
ment on SE-derived NPC behavior. Uninjured pups that
received metformin through the mother’s milk for 4 days
(from P9–12) had a 2-fold increase in the number of neuro-
spheres (stem cell pool expansion), similar to what was
observed in culture (Figure 1A). As predicted, subcutaneous
metformin injections given to CBP S436Amutantmice did
not result in expansion of the stem cell pool (Figure 2D).ell Reports j Vol. 5 j 166–173 j August 11, 2015 j ª2015 The Authors 167
Figure 2. Metformin Treatment following Injury Rescues Motor Deficits, In Vivo
(A) Experimental paradigm of injury and metformin treatment. Metformin was administered 1 day following injury to lactating mothers.
(B) Mice were tested on their ability to flip from supine position to prone position 1 hr after H/I (n = 11 mice/group, t test).
(C) Latency to fall from the edge of the tube was compared between different treatment groups (nR 6 mice/group, t test).
(D) Expansion of the SE-derived NPC pool in metformin-treated mice (n = 6 mice/group, t test). This metformin-induced expansion of the
SE-derived NPC pool was lost in CBP S436A mutants (nR 12 mice/group, t test).
(E) An H/I injury alone expanded the stem cell pool (n = 5 mice/group, two-way ANOVA).
(F) The cylinder-rearing test was used to assess sensory-motor function. Graph depicts non-impaired forepaw preference for mice tested on
day 22 (n R 7 mice/group, one-way ANOVA). Met, metformin; CL, contralateral hemisphere to ischemia; IL, ipsilateral hemisphere to
ischemia. Data are presented as mean ± SEM. *p < 0.05, **p < 0.01.
See also Figure S1.H/I injury alone increased the size of the NSC pool (R4-
fold increase) both ipsilateral (IL) and contralateral (CL)
to the ischemic insult. Interestingly, H/I + metformin-
treated pups gave rise to reduced numbers of SE-derived
neurospheres relative to the H/I treatment (although
similar to metformin-only-treated mice) (Figure 2E). One
potential explanation for this relative decrease is that
metformin promoted the migration of endogenous NPCs
into the surrounding parenchyma. In support of this hy-
pothesis, when we performed the neurosphere assay from
cortical tissue, we observed a complete lack of neuro-
spheres from control (uninjured) and metformin-only-
treated mice, whereas neurospheres were consistently
generated from the frontal cortices of H/I + metformin-
treated pups (5.0 ± 2.5 neurospheres/cortices).
We then asked whether metformin treatment was able
to promote functional recovery. Notably, 4 days of metfor-
min treatment (P9–12) was not sufficient to improve the
motor impairment in the hind-limb suspension task in168 Stem Cell Reports j Vol. 5 j 166–173 j August 11, 2015 j ª2015 The AutH/I-injured pups (Figure 2C). In contrast, mice that
received 7 days of metformin treatment (P9–15) displayed
significant recovery in forelimb function when tested in
the cylinder task 2 weeks after the lesion (P22) (Figure 2F).
Mice that experienced H/I alone displayed a significant
preference for use of the IL, unimpaired paw. Indeed,
the performance of metformin-treated mice was not sta-
tistically different from uninjured controls. To ensure
the functional recovery observed in metformin-treated
mice was not due to secondary effects, H/I-injured pups
received subcutaneous injections of metformin from
P9–15. As was seen following exposure to metformin via
the mother’s milk, we observed recovery in metformin-
injected H/I mice, indicating a direct effect of metformin.
Next, we asked if this functional recovery was mediated
by activation of the aPKC-CBP pathway. Most strikingly,
CBP S436A mutants that received subcutaneous injections
of metformin from P9–15 following H/I injury did not
display functional recovery compared to CBP S436Ahors
mutants that had an H/I injury (Figure 2F). Hence, met-
formin promoted functional recovery via the aPKC-CBP
pathway.
Metformin Promotes Expansion, Migration, and
Differentiation of Endogenous NPCs in the Injured
Brain
To determine the cellular basis for this restored function on
the sensory-motor task, we performed lineage-tracking ex-
periments usingNestin-CreERT2/R26R-YFP transgenic mice.
When these mice are exposed to tamoxifen, this leads to
recombination and expression of YFP in nestin-expressing
NPCs and all of their progeny. To perform the lineage
tracing, we provided tamoxifen to lactating mothers in
their food chow, and thereby exposed their neonatal
pups to tamoxifen shortly after birth. At P8, prior to H/I,
the vast majority of YFP-positive cells were confined to
the SE in the brains of these offspring (Figure S2A). Groups
of tamoxifen-treated pups received H/I with or without
metformin treatment and their brains were examined at
P16 (immediately after metformin treatment, Figures
S2B–S2F) and at P23 (time of observed functional recovery,
Figure 3A). At both day 16 and 23, H/I + metformin-treated
mice had more SE-derived YFP-positive cells in all areas
examined, in both the IL and CL parenchyma. At the
time of functional recovery (P23), H/I + metformin pups
displayed significant increases in YFP-positive cells in the
olfactory bulb and subventricular zone and an increasing
trend in the hippocampuswhereNPCs and ongoing neuro-
genesis are normally observed (Figures S2G–S2K). Similarly,
we observed significant increases in YFP-positive cells in
regions of the brain known to play a role inmotor activities
(striatum, corpus callosum, and the motor cortex)
compared to H/I-only- and metformin-only-treated mice
(>4-fold in all areas) (Figures 3B and 3E). Indeed, H/I-only
and metformin-only brains had very few YFP-positive cells
in the parenchyma and were not significantly different
from each other (Figure 3B).
We examined the differentiation profile of the SE-
derived, YFP-positive cells by counting the numbers of neu-
rons (YFP+/NeuN+) and oligodendrocytes (YFP+/MBP+
and YFP+/Olig2+). Neurogenesis and oligodendrogenesis
were not significantly different in any region examined be-
tween H/I-only- and metformin-only-treated brains (Fig-
ures 3C and 3D). However, we consistently observed signif-
icantly increased numbers of differentiated cells in H/I +
metformin-treated mice IL and CL to the lesion (Figures
3C–3G), with the exception of neurogenesis in the motor
cortex.Most strikingwas the dramatic increase in oligoden-
drogenesis in H/I + metformin-treated mice in both hemi-
spheres in the striatum (6-fold CL, 23-fold IL), motor cortex
(10-fold CL, 6-fold IL), and corpus callosum (8-fold CL,
3-fold IL) (Figures 3D and 3G). The increased oligodendro-Stem Ccyte formation inH/I +metformin-treatedmicewas further
assessed usingwestern blots. As seen in Figure S2L, the level
of MBP was markedly increased in the H/I + metformin
group relative to control H/I.
To understand the effect of metformin underlying func-
tional recovery, we analyzed the relative percentage of
YFP+ cells that differentiated into oligodendrocytes and
neurons in the striatum, corpus callosum, and motor cor-
tex, between H/I- and H/I + metformin-treated brains (Fig-
ure 3H). Notably, while the total numbers of SE-derived,
YFP+ cells within the brain parenchyma were dramatically
different between H/I- and H/I + metformin-treated mice,
we observed no difference in the relative percentage of
differentiated cell types within the parenchyma. Further,
we found the relative distribution of SE-derived YFP+ cells
to be similar between H/I-only- versus H/I + metformin-
treated brains, with themajority of cells found in the olfac-
tory bulb (Figure S2M). Taken together, these findings
suggest that it is the magnitude of the contribution of
newborn cells to the brain tissue that correlates with the
functional recovery observed in H/I + metformin-treated
pups (Figure S2N).DISCUSSION
Our findings indicate that endogenous NPC activation
following injury is able to promote self-repair and func-
tional recovery in a rodent model of childhood brain
injury. We demonstrate metformin treatment in the
neonatal brain for 7 days can lead to expansion and migra-
tion into the brain parenchyma of NPCs that play a role in
sensory-motor function.
Drug therapy for the H/I-injured brain has focused
largely on anti-oxidants (allopurinol, N-acetylcysteine),
anti-excitotoxic agents (topiramate, memantine), and
anti-inflammatory agents (cromolyn) (Juul and Ferriero,
2014; Hagberg et al., 2015). These therapies have been
shown to primarily mediate their effects through neuro-
protection and have resulted in varying degrees of func-
tional recovery and a reduction in infarct volume. Further,
while they display similarities in cost-effectiveness, impli-
cations in different injury models, and success in adults
or old age animals, metformin is the only drug treatment
that has demonstrated efficacy in generating new cells in
the neonatal brain. Metformin may confer additional ad-
vantages such as improving lifespan (Martin-Montalvo
et al., 2013) and promoting angiogenesis (Jin et al., 2014;
Liu et al., 2014; Venna et al., 2014).
The finding that metformin, an anti-diabetic drug, in-
creases the absolute number of NPCs following injury
(rather than changing the relative percentage of differen-
tiated cells) was surprising. Several possibilities couldell Reports j Vol. 5 j 166–173 j August 11, 2015 j ª2015 The Authors 169
Figure 3. Metformin Increases the Absolute Numbers of SE-Derived NPCs in the Brain Parenchyma following Injury
(A) Experimental design for metformin administration and behavioral testing. Lineage tracing of SE-derived cells used Nestin-CreERT2/
R26R-YFP transgenic mice.
(B) Quantification of SE-derived YFP+ cells found in the striatum (nR 3 mice/group, two-way ANOVA), motor cortex (nR 3 mice/group,
two-way ANOVA), and corpus callosum (nR 3 mice/group, two-way ANOVA) is shown.
(C) Quantification of YFP+ cells that were co-labeled with NeuN, indicating newborn neurons, in striatum (nR 3 mice/group, two-way
ANOVA) and motor cortex (nR 3 mice/group, two-way ANOVA) is shown.
(D) Quantification of YFP+ cells that were co-labeled with Olig2+ or MBP+, indicating newborn immature or mature oligodendrocytes,
respectively, in striatum (nR 3 mice/group, two-way ANOVA), motor cortex (nR 3 mice/group, two-way ANOVA), and corpus callosum
(nR 3 mice/group, two-way ANOVA) is shown.
(E–G) Coronal sections immunostained for YFP+ cells (green) and Hoechst (blue) (E); YFP+ (green), NeuN (red), and Hoechst (blue) (F); and
YFP+ (green), Olig2+/MBP+ (red), and Hoechst (blue) (G) are shown.
(H) The relative percentages of differentiated neurons (striatum and motor cortex) and differentiated oligodendrocytes (striatum, motor
cortex, and corpus callosum) were not significantly different between groups. IL and CL hemispheres were pooled together (nR 4 mice/
group, t test). Arrows denote labeled cells. Scale bars, 20 mm. Data are presented as mean ± SEM. TAM, tamoxifen; ST, striatum; MC, motor
cortex; CC, corpus callosum. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
See also Figure S2.account for this observation. For example,metformin could
have direct effects on NPCs (such as changes in cell-cycle
kinetics and/or promoting cell survival) or indirect effects170 Stem Cell Reports j Vol. 5 j 166–173 j August 11, 2015 j ª2015 The Auton non-NPCs that leads to the release of growth/trophic
factors, providing immunomodulation, neuroprotection,
and/or angiogenesis, which could effectively lead to anhors
expansion in the size of the NPC pool. Indeed with respect
to the latter, recent studies using chronic metformin
treatment in adult ischemia models have demonstrated
enhanced angiogenesis/neurogenesis correlating with mo-
tor function recovery (Jin et al., 2014; Liu et al., 2014).
Given that the developing brain is known to exhibit a
greater degree of plasticity (Kolb and Gibb, 2011) and a
greater number of resident NPCs compared to the adult
brain (Sachewsky et al., 2014), it is plausible that similar
mechanisms of enhanced angiogenesis and neurogenesis
are occurring in our H/I injury model.
Metformin is a safe, FDA-approved drug, which supports
the translation of these findings to the clinic in a reason-
able time frame. The therapeutic window for metformin
treatment and long-term outcomes, both at the cellular
and behavioral levels, will be important considerations
for future studies. Further, studies to determine whether
metformin treatment can ameliorate cognitive impair-
ments that result followingH/I will be important to pursue.
Our findings provide compelling support for exploring
endogenous NPC activation using metformin for the treat-
ment of childhood brain injury.EXPERIMENTAL PROCEDURES
Animals
C57/BL6, CD1 pregnantmice were purchased (Charles River Labo-
ratories) and maintained under pathogen-free conditions. CBP
S46A and Nestin-CreERT2/R26R-YFP transgenic mice were bred in
an animal facility. Tamoxifen at a dose of 0.5 mg/kg was mixed
inwith rodent chow. Allmicewere kept on a 12-hr day/night cycle,
and procedures were performed in accordance with institutional
guidelines approved by the Experimental Animal Committee at
the University of Toronto.
H/I Injury Model
Briefly, the left common carotid artery of P8 pups was ligated to
give an ischemic insult. Following a 1.5-hr recovery, they were sub-
jected to hypoxia for 1 hr at a temperature of 36C. Pre-established
endpoints were excluded from statistical analysis.
Metformin Administration
For the in vitro neurosphere assay, metformin stock solution was
prepared by dissolving in serum-free media (SFMs) and added to
culture at various concentrations. In vivo metformin was adminis-
tered, through a micro-osmotic pump implanted subcutaneously
into the mother, at a concentration of 20 mg/kg/day for 7 days.
The pups receivedmetformin through themother’smilk. For injec-
tion studies, metformin at the above concentration was injected
subcutaneously into the pups daily for 7 days.
Neurosphere and Cortical Assay
NSCs were isolated by dissecting the neonatal SE from P8 and P12
animals, as previously described (Morshead et al., 2002), andStem Cgrown in the presence of mitogens for 7 days. For differentiation
assays, individual neurospheres were collected from each condi-
tion and plated in the presence of 10% fetal bovine serum (FBS)
and the presence and absence of metformin for 7 days. For the
cortical assay, the SE was carefully dissected and discarded to
ensure no contaminating SE-derived neurospheres were grown in
culture. Portions of the cortex were then dissected and processed.
Tissue Preparation and Immunohistochemistry
Animals were sacrificed with an overdose of sodium pentobar-
bital, perfused with 4% paraformaldehyde at different time points
(P8, P16, and P23), and cryoprotected in 20% sucrose overnight at
4C. Coronal, cryostat sections (20 mm) were mounted on Super-
frost Plus slides and stained. Briefly, brain sections were rehy-
drated for 5 min and permeabilized using 0.3% Triton in PBS
for 20 min, rinsed, and then blocked with 1% BSA containing
0.3% Triton in PBS at room temperature. Brain sections were
incubated with primary antibodies overnight at 4C in 1% BSA
with 0.3% Triton in PBS. The next day slides were washed and
incubated with an appropriate secondary antibody for 2 hr at
room temperature, washed, and mounted with DAPI-mounting
media. A Zeiss Observer D1 inverted microscope was used to
visualize immunofluorescence for differentiated neurospheres
and tissue sections. Images were acquired at 203 objective using
Axio Vision.
Behavioral Testing
The righting-reflex, hind-limb suspension test was performed as
described previously (El-Khodor et al., 2008; Ten et al., 2003).
The cylinder-rearing test was used evaluate functional asymmetry
resulting from unilateral brain lesion and consequent hemiplegia
at P22. Mice were individually placed in a Plexiglas transparent
cylinder and video recorded for 4 min or until they reached
ten touches per paw. The relative proportion of left (IL) forepaw
contacts was calculated as follows: (left – right)/(right + left +
both) 3 100.
Statistical Analysis
Data were analyzed using Prism Software (version 6, GraphPad).
An unpaired Student’s t test was used for two-group comparisons.
A one-way ANOVA was used for multiple-group comparisons fol-
lowed by Bonferroni’s post hoc test. For analysis comparing CL
and IL hemispheres, a two-way ANOVA was performed followed
by Tukey’s multiple comparisons test. A statistically significant
level was defined as p < 0.05. Error bars are reported as mean ±
SEM unless stated otherwise.
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